Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

International Journal of Cancer

Volumn 105, Issue 3, 2003, Pages 394-399

  Otto, Suzie J ^a   Van Der Cruijsen, Ingrid W ^a   Liem, Michael K ^a   Korfage, Ida J ^a   Lous, Jan J ^b   Schröder, Fritz H ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Laboratory   (Netherlands)

Author keywords

Contamination; ERSPC trial; Opportunistic; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC TEST; EUROPE; FEMALE; GENERAL PRACTICE; HEALTH CARE SYSTEM; HISTOLOGY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE GENITAL TRACT CANCER; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; BIOPSY; CLINICAL TRIALS; DATABASES; EUROPE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0038558404     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11074     Document Type: Article

References (16)

1. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA." Int J Cancer 2001;92:893-8.
2. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38:83-91.
3. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001;58:417-24.
4. de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais Da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237-44.
5. Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, van der Maas PJ, Schröder FH. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer. Rotterdam. J Urol 2000;164:1216-20.
6. Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schröder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 1999;84:437-41.
7. Bartelds AIM. Prostaatlijden continue morbiditeits registratie peilstations Nederland 2000. Utrecht: NIVEL, 2001. 105-8.
8. Van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. J Epidemiol 1990;19:553-8.
9. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. vol. 7. Lyon: IARC, 1997.
10. Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction: a registry-based study in southeastern Netherlands, 1971-1995. Eur J Cancer 1998;34:7059.
11. de. Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE, et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98:268-73.
12. Faulkner A, Brookes ST, Donovan J, Selley S, Gillat D, Hamdy F. The use of prostate-specific antigen testing in the detection of localized prostate cancer: current opinion and urological practice in the United Kingdom. Eur J Pub Health 2000;10:289-95.
13. IPSTEG. Rationale for randomised trials of prostate cancer screening: the International Prostate Screening Trial. Evaluation Group. Eur J Cancer 1999:35:262-71.
14. Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer: validation of screening without rectal examination. Urology 2001;57:83-90.
15. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 2002;59:251-5.
16. Páez A, Luján M, Llanes L, Romereo I, de la Cal MA, Miravalles E, et al. PSA-use in a Spanish industrial area. Eur Urol 2002;41:162-6.